14th October 2021
Consilium Strategic Communications advises SparingVision on its strategic collaboration with Intellia Therapeutics
Collaboration to develop novel ocular therapies using CRISPR/Cas9 technology
London, 14 October 2021, Consilium Strategic Communications, a global leader in strategic healthcare communications and investor relations, is pleased to have advised SparingVision, a genomic medicine company developing vision saving treatments for ocular diseases, on its strategic collaboration with Intellia Therapeutics. Intellia is a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology. The collaboration will see the two companies develop novel genomic medicines using CRISPR/Cas9 technology for the treatment of ocular diseases.
The partnership is highly complementary to SparingVision’s mature and growing pipeline of unique mutation-agnostic gene therapies and combines SparingVision’s significant ophthalmology expertise with Intellia’s proprietary genome editing technology platform. Under the terms of the agreement, Intellia will grant SparingVision exclusive rights to its leading in vivo CRISPR/Cas9-based genome editing technology for up to three ocular targets addressing diseases with significant unmet medical need. SparingVision will lead and fund the preclinical and clinical development for these genome-editing product candidates.
The team advising SparingVision at Consilium was Amber Fennell, Genevieve Wilson, Davide Salvi, Priit Piip and Isobel McLeod. Beyond this announcement, Consilium has provided ongoing strategic financial and corporate communications support to SparingVision, notably advising the company on its acquisition of GAMUT Therapeutics in April 2021 and its €44.5 million fundraise in October 2020.
“This collaboration marks a significant step for SparingVision as it aims to bring the most cutting edge of modern science to patients who are losing their sight and have no other options. With Intellia’s cutting-edge technology, SparingVision can further enhance its pipeline, becoming a key player in ocular genomic medicines. We are very proud to be working with the SparingVision team to communicate their story globally.”
Amber FennellPartner and Co-Founder of Consilium Strategic Communications
“We want to extend a huge thank you to the Consilium team for their strategic advice and guidance through the communication of this collaboration. SparingVision is now well on its way to leading a step shift in the treatment of ocular diseases and we look forward to continuing working with Consilium as we move to this exciting next stage of development.”
Stéphane BoisselChief Executive Officer of SparingVision
- ENDS -
For more information, please contact:
Consilium Strategic Communications
Mary-Jane Elliott / Amber Fennell
Tel: +44(0)20 3709 5700
About Consilium Strategic Communications
Consilium Strategic Communications is a global leader in strategic healthcare communications and investor relations advisory with offices in Europe and across the US. Consilium's highly skilled team provides strategic, long-term advice to healthcare companies, Boards, senior decision makers and executives on critical communications and IR programmes and stakeholder challenges. The Company has established deep knowledge across all areas of the global healthcare sector through broad experience in representing international clients spanning the Fortune 500, FTSE 100, FTSEurofirst 300 and FTSE 250, through to discrete specialist reputation management projects.
SparingVision is a genomic medicines company, translating pioneering science into vision-saving treatments. Founded to advance over 20 years of world-leading ophthalmic research from its scientific founders at the Paris Vision Institute, SparingVision is leading a step shift in how ocular diseases are treated, moving beyond single gene correction therapies. At the heart of this is a pipeline of gene independent treatments for rod-cone dystrophies. Lead products, SPVN06 and SPVN20, address mid and late stages of retinitis pigmentosa (RP)respectively. RP is the most common inherited retinal disease affecting two million people worldwide. These novel medicines could form the basis of a suite of new sight-saving treatments with potential applications across many other retinal diseases, regardless of genetic cause.
The Company is supported by a strong, internationally renowned team who aim to harness the potential of genomic medicine to deliver new treatments to all ocular disease patients as quickly as possible. SparingVision has raised €60 million to date and its investors include 4BIO Capital, Advent France Biotechnology, Bpifrance, Foundation Fighting Blindness (US), Fondation Voir & Entendre, UPMC Enterprises, Jeito Capital and Ysios Capital. For more information, please visit www.sparingvision.com.